D. Schrag

Deborah Schrag, Edward S. Kim, Edward S Kim, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Adam P Dicker, Thomas J. Smith, Gary H Lyman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Thomas J. Smith, J. Vose, R. Schilsky, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.

Deborah Schrag, Allison Barz, Ethan Basch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Deborah Schrag, Allison Barz, Ethan Basch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation.

D. Schrag, D. Sher, Aileen B Chen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.

Deborah Schrag, Ahmedin Jemal, Elizabeth Ward, 2005, Journal of the National Cancer Institute.

Patient online self-reporting of toxicity symptoms during chemotherapy.

Nandita Mitra, David Artz, Deborah Schrag, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant C hemotherapy U se f or M edicare B eneficiaries With S tage I I C olon C ancer

C. Begg, L. Saltz, D. Schrag, 2002 .

Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers.

J. Niland, M. Weiser, J. Skibber, 2014, Journal of the National Cancer Institute.

The surgical learning curve for prostate cancer control after radical prostatectomy

M. Kattan, P. Scardino, J. Eastham, 2008 .

Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model

M. Ezzati, K. Kuntz, D. Schrag, 2013, PLoS medicine.

Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer.

T. Jang, M. Zelefsky, E. Basch, 2007, International journal of radiation oncology, biology, physics.

The APCI1307K allele and breast cancer risk.

M. King, J. Satagopan, W. Foulkes, 1998, Nature genetics.

Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.

D. Schrag, D. Sher, Aileen B Chen, 2011, International journal of radiation oncology, biology, physics.

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.

J. Niland, A. Benson, M. Weiser, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.

D. Schrag, M. Hassett, G. Brooks, 2018, Health services research.

Risk charts: putting cancer in context.

D. Schrag, P. Bach, 2002, Journal of the National Cancer Institute.

Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer.

F. Boscoe, M. Schymura, F. Gesten, 2012, Journal of the National Cancer Institute.

onlineDeCISion.org: a web-based decision aid for DCIS treatment

D. Schrag, N. Stout, E. Ozanne, 2015, Breast Cancer Research and Treatment.

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

Hajime Uno, Deborah Schrag, John Kidd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

D. Schrag, Leah H. Biller, 2021, JAMA.

Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of CancerA Multi-institutional Cohort StudyInterinstitutional Variation in Cancer Management Decisions

H. Uno, J. Friedberg, D. Schrag, 2014 .

A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.

P. Enzinger, D. Schrag, N. Meropol, 2017, Patient education and counseling.

Comment on: Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. Authors' reply

C. Ko, Seung-Yong Jeong, J. Guillem, 2005 .

Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.

M. Kris, C. Hudis, E. Basch, 2017 .

The Evolving Uses of "Real-World" Data.

E. Basch, D. Schrag, 2019, JAMA.

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

J. Meyerhardt, P. Fidias, J. Temel, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Reliability of adverse symptom event reporting by clinicians

M. Gönen, E. Basch, A. Bennett, 2012, Quality of Life Research.

Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).

Arlene E. Chung, E. Basch, W. Wood, 2021, Lung cancer.

Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States

K. Kuntz, D. Schrag, E. Aas, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources

J. Warren, D. Schrag, P. Bach, 2002, Medical care.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

K. Kahn, J. Niland, J. Meyerhardt, 2012, Journal of the National Cancer Institute.

Cetuximab therapy and symptomatic hypomagnesemia.

L. Saltz, D. Schrag, K. Chung, 2005, Journal of the National Cancer Institute.

Evaluating the impact of organizational changes in health care delivery: challenges in study design.

D. Schrag, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Centralization of cancer surgery: what does it mean for surgical training?

S. Ashley, C. Greenberg, D. Schrag, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma.

V. Rusch, M. Bains, D. Schrag, 2004, Journal of the American College of Surgeons.

Receipt of appropriate surgical care for Medicare beneficiaries with cancer.

S. Lipsitz, A. Gawande, A. Jha, 2011, Archives of surgery.

Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.

T. D. de Reijke, E. Basch, T. Steuber, 2015, European urology.

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.

D. Schrag, K. Kehl, C. Lathan, 2018, Journal of the National Cancer Institute.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

K. Kahn, J. Niland, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival of blacks and whites after a cancer diagnosis.

Colin B Begg, Deborah Schrag, Peter B Bach, 2002, JAMA.

Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data

D. Schrag, K. Panageas, G. Heller, 2010 .

Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population

Deborah Schrag, C. Klabunde, J. Warren, 2002, Medical care.

Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations

E. Guadagnoli, J. Warren, D. Schrag, 2002, Medical care.

Deep natural language processing to identify symptom documentation in clinical notes for patients with heart failure undergoing cardiac resynchronization therapy.

Ashwin Ramaswamy, D. Schrag, C. Lindvall, 2020, Journal of pain and symptom management.

Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

M. Gonen, K. Goodman, P. Paty, 2010 .

An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.

M. Weiser, D. Schrag, T. Akhurst, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving Rectal Cancer Outcomes with Chemotherapy

D. Schrag, 2005 .

Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor

Laura H. Tang, J. Guillem, P. Paty, 2007, Diseases of the colon and rectum.

Evolving Role of Neoadjuvant Therapy in Rectal Cancer

D. Schrag, 2013, Current Treatment Options in Oncology.

Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

M. Somerfield, A. Benson, D. Haller, 2004 .

Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers

J. Niland, A. Benson, K. Goodman, 2017, Advances in radiation oncology.

Factors Associated With Sphincter-Preserving Surgery for Rectal Cancer at National Comprehensive Cancer Network Centers

J. Niland, A. Benson, L. Temple, 2009, Annals of surgery.

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

K. Kahn, S. Grambow, P. Catalano, 2011, BMC Cancer.

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy.

A. Benson, M. Weiser, J. Skibber, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial

J. Meyerhardt, C. Fuchs, A. Bullock, 2019, JAMA.

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

M. Somerfield, E. Van Cutsem, A. Benson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.

Yuman Fong, Jerome Seidenfeld, Michael A Choti, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE).

A. Abernethy, L. Minasian, E. Basch, 2010 .

Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).

H. Uno, G. Abel, D. Schrag, 2014, Leukemia research.

Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries

D. Schrag, M. Halpern, 2016, Breast Cancer Research and Treatment.

Defining optimal treatment for stage II colon cancer: does decision analysis help?

D. Schrag, 1999, Gastroenterology.

Acute kidney injury in patients treated with immune checkpoint inhibitors

D. Leaf, D. Schrag, Shruti Gupta, 2021, Journal for ImmunoTherapy of Cancer.

Re: Risk Charts: Putting Cancer in Context

D. Schrag, P. Bach, 2002 .

Cancer and Leukemia Group B Cancer Control and Health Outcomes Committee: Origins and Accomplishments

J. Holland, E. Lamont, C. Shapiro, 2006, Clinical Cancer Research.

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

P. Pandharipande, D. Ryan, D. Schrag, 2017, The oncologist.

Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study

Arlene E. Chung, A. Abernethy, E. Basch, 2018, JMIR human factors.

Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial–Ready Patients With Cancer

E. V. Van Allen, D. Schrag, K. Kehl, 2021, JCO clinical cancer informatics.

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

Jeffrey W. Clark, A. Iafrate, J. Meyerhardt, 2011, Cancer.

Dartmouth Atlas Area-Level Estimates of End-of-Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients?

D. Haggstrom, N. Keating, P. Maciejewski, 2016, Health Services Research.

Prophylactic mastectomy in carriers of BRCA mutations.

K. Offit, D. Schrag, M. Robson, 2001, The New England journal of medicine.

Accelerating anticancer drug development — opportunities and trade-offs

A. Abernethy, H. Hricak, K. Anderson, 2018, Nature Reviews Clinical Oncology.

Identifying cancer patients who alter care or lifestyle due to treatment‐related financial distress

A. Abernethy, G. Samsa, D. Schrag, 2016, Psycho-oncology.

Communication and coordination: the keys to quality.

D. Schrag, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation therapy facilities in the United States.

E. Elkin, D. Schrag, P. Bach, 2006, International journal of radiation oncology, biology, physics.

Building capacity to assess cancer care in the Medicaid population in New York State.

Deborah Schrag, Francis P Boscoe, F. Boscoe, 2011, Health services research.

Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California.

F. Boscoe, M. Schymura, F. Gesten, 2013, Journal of Clinical Oncology.

The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients

E. Feuer, A. Mariotto, B. Hankey, 2012, Cancer.

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

C. Klabunde, J. Warren, J. Legler, 2007, Annals of epidemiology.

Lack of Association Between Heart Failure and Incident Cancer.

Deepak L. Bhatt, Sanjiv J. Shah, H. Sesso, 2018, Journal of the American College of Cardiology.

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

C. Begg, D. Schrag, P. Bach, 2001, Journal of the National Cancer Institute.

How much can current interventions reduce colorectal cancer mortality in the U.S.?

Deborah Schrag, Ann G Zauber, Marjolein van Ballegooijen, 2006, Cancer.

Oncology Practice During the COVID-19 Pandemic.

E. Basch, D. Schrag, D. Hershman, 2020, JAMA.

Missed opportunities: racial disparities in adjuvant breast cancer treatment.

D. Schrag, N. Bickell, Jason J. Wang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence

J. Meyerhardt, P. Catalano, A. Benson, 2003, Annals of Internal Medicine.

Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection

C. Begg, J. Guillem, D. Schrag, 2003, Journal of surgical oncology.

Adherence to surveillance among patients with superficial bladder cancer.

Colin B Begg, Deborah Schrag, Peter B Bach, 2003, Journal of the National Cancer Institute.

Factors Contributing To Geographic Variation In End-Of-Life Expenditures For Cancer Patients.

D. Haggstrom, N. Keating, M. Landrum, 2018, Health affairs.

Catalog and Comparison of Societal Preferences (Utilities) for Lung Cancer Health States

D. Schrag, P. McMahon, J. Weeks, 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

C. Begg, L. Saltz, D. Schrag, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes

C. Begg, D. Schrag, P. Bach, 2003, Annals of Internal Medicine.

Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.

C. Begg, J. Guillem, D. Schrag, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variations in morbidity after radical prostatectomy.

Colin B Begg, Deborah Schrag, Michael W Kattan, 2002, The New England journal of medicine.

Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection

C. Begg, J. Guillem, D. Schrag, 2002, Annals of surgery.

The relationship between primary tumor sidedness and prognosis in colorectal cancer.

J. Meyerhardt, A. Venook, D. Schrag, 2016 .

Racial disparities in colorectal cancer recurrence and mortality: equitable care, inequitable outcomes?

D. Schrag, Christopher R Manz, 2020, Journal of the National Cancer Institute.

ASO Author Reflections: Patient-Reported Outcomes—Bench to Bedside

D. Schrag, S. Wong, S. Ivatury, 2019, Annals of Surgical Oncology.

Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer.

A. Abernethy, G. Samsa, D. Schrag, 2013, Journal of oncology practice.

Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

J. Niloff, R. Berkowitz, J. Garber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Occult O varian T umors i n W omen W ith BRCA1 or BRCA2 Mutations U ndergoing P rophylactic O ophorectomy

J. Niloff, R. Berkowitz, J. Garber, 2000 .

Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients

Angela Mariotto, Deborah Schrag, A. Mariotto, 2016, Medical care.

Accuracy and completeness of diagnosis codes for cancer metastasis on Medicare claims.

A. Mariotto, J. Warren, D. Schrag, 2013 .

Geographic Access and the Use of Screening Mammography

Elena B. Elkin, Fahui Wang, Deborah Schrag, 2010, Medical care.

Testing for inherited cancer susceptibility.

J. Garber, D. Schrag, 1996, JAMA.

PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

A. Abernethy, L. Minasian, E. Basch, 2010 .

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial

C. Sima, M. Kris, E. Basch, 2016, Clinical trials.

Reply to F. Fiorica et al and D. Vordermark.

D. Schrag, A. B. Chen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer screening among patients with advanced cancer.

C. Sima, D. Schrag, K. Panageas, 2010, JAMA.

Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.

M. Levy, F. Meric-Bernstam, F. André, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

A. Abernethy, D. Schrag, J. Peppercorn, 2013, The oncologist.

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma.

Rachel B. Keller, W. Hahn, M. Meyerson, 2021, Cancer discovery.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

L. Minasian, E. Basch, A. Bennett, 2017, International journal of radiation oncology, biology, physics.

Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps.

J. Garber, N. Tung, D. Schrag, 2000, JAMA.

Precision Prevention and Early Detection of Cancer: Fundamental Principles.

Peter Kraft, Giovanni Parmigiani, Francine Laden, 2018, Cancer discovery.

Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC).

J. Meyerhardt, C. Fuchs, A. Zhu, 2010 .

Variation in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists.

D. Schrag, Aileen B Chen, S. Giordano, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

An ED pilot intervention to facilitate outpatient acute care for cancer patients.

D. Schrag, Mark A. Murakami, C. Baugh, 2016, The American journal of emergency medicine.

Examining the relationship between complications and perioperative mortality following radical cystectomy: a population‐based analysis

Steven L. Chang, A. Kibel, G. Sonpavde, 2019, BJU international.

Impact of out-of-pocket expenses on cancer care.

A. Abernethy, D. Schrag, J. Peppercorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer-Reply.

D. Schrag, Leah H. Biller, 2021, JAMA.

Incorrect Positive Predictive Values Reported.

D. Schrag, Leah H. Biller, 2021, JAMA.

FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial

Jeffrey W. Clark, C. Azzoli, J. Meyerhardt, 2019, Cancer.

Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.

J. Meyerhardt, C. Fuchs, D. Schrag, 2017, The oncologist.

Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN) analysis.

J. Niland, A. Benson, M. Weiser, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer

J. Bacik, H. Thaler, J. Guillem, 2005, Diseases of the colon and rectum.

Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).

J. Meyerhardt, C. Fuchs, P. Enzinger, 2018 .

Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer.

L. Saltz, D. Schrag, B. Minsky, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncology Drug Effectiveness from Electronic Health Record Data Calibrated Against RCT Evidence: The PARSIFAL Trial Emulation

S. Schneeweiss, D. Schrag, Kueiyu Joshua Lin, 2022, Clinical epidemiology.

Reimbursing Wisely? CMS's Trial of Medicare Part B Drug Payment Reform.

D. Schrag, 2016, The New England journal of medicine.

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

D. Schrag, D. Farge, C. Frère, 2022, Journal of Hematology & Oncology.

Progress in the PROSPECT trial: precision treatment for rectal cancer?

J. Boughey, M. Weiser, A. Fichera, 2015, Bulletin of the American College of Surgeons.

Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation.

K. Goodman, J. Guillem, P. Paty, 2010 .

SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer.

C. Fuchs, E. Chan, D. Schrag, 2017 .

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.

J. Meyerhardt, P. Enzinger, D. Schrag, 2014, The oncologist.

Quality of life and function after rectal cancer surgery with and without sphincter preservation

J. Guillem, G. Nash, L. Temple, 2022, Frontiers in Oncology.

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.

B. Given, A. Bennett, D. Cella, 2022, JAMA.

Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

M. Bertagnolli, E. Basch, A. Bennett, 2020, Clinical trials.

Outcome of toxic dilatation in ulcerative and Crohn's colitis.

D. Schrag, D. Sachar, H. Janowitz, 1985, Journal of clinical gastroenterology.

An algorithm to predict data completeness in oncology electronic medical records for comparative effectiveness research.

S. Schneeweiss, J. Lii, D. Schrag, 2022, Annals of epidemiology.

Patient-oncologist cost communication, financial distress, and medication adherence.

A. Abernethy, J. Tulsky, P. Ubel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty.

D. Schrag, K. Ng, Folasade P. May, 2021, JAMA.

Overview of the SEER-Medicare Data

C. Klabunde, J. Warren, D. Schrag, 2002 .

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Alexia Iasonos, Xiaoyu Jia, Deborah Schrag, 2009, Journal of the National Cancer Institute.

Costs and cost-effectiveness of colorectal cancer prevention and therapy.

D. Schrag, J. Weeks, 1999, Seminars in oncology.

The utility of cost discussions between patients with cancer and oncologists.

A. Abernethy, J. Tulsky, P. Ubel, 2015, The American journal of managed care.

Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405.

A. Kesselheim, R. Goldberg, A. Venook, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locally advanced rectal cancer: time for precision therapeutics.

M. Weiser, D. Schrag, Zhen Zhang, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer.

P. Maciejewski, H. Prigerson, S. Block, 2009, JAMA.

Using navigators to improve care of underserved patients

D. Schrag, D. Dohan, 2005, Cancer.

Patients' expectations about effects of chemotherapy for advanced cancer.

Matthew D Finkelman, Paul J Catalano, Deborah Schrag, 2012, The New England journal of medicine.

Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies

M. Berry, D. Harpole, D. Schrag, 2017, Journal of the National Cancer Institute.

Hierarchical Models for Semicompeting Risks Data With Application to Quality of End-of-Life Care for Pancreatic Cancer

Kyu Ha Lee, Francesca Dominici, Deborah Schrag, 2015, Journal of the American Statistical Association.

Bayesian semiparametric analysis of semicompeting risks data: investigating hospital readmission after a pancreatic cancer diagnosis

Kyu Ha Lee, Francesca Dominici, Deborah Schrag, 2015, Journal of the Royal Statistical Society. Series C, Applied statistics.

Diffusion of Bevacizumab Across Oncology Practices: An Observational Study

B. McNeil, S. Normand, N. Keating, 2018, Medical care.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Amy P Abernethy, Tito R Mendoza, Charles S Cleeland, 2015, JAMA oncology.

Influence of hospital procedure volume on outcomes following surgery for colon cancer.

C. Begg, J. Warren, D. Schrag, 2000, JAMA.

Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation.

D. Schrag, P. Bach, J. Groeger, 2001, Blood.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Amy P Abernethy, Ram Chilukuri, Tito R Mendoza, 2014, Journal of the National Cancer Institute.

Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer.

Deborah Schrag, D. Schrag, J. Ayanian, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.

Mithat Gönen, Deborah Schrag, M. Gönen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individualized prediction of colon cancer recurrence using a nomogram.

Mithat Gonen, Deborah Schrag, Jinru Shia, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

O. W. Lindwasser, J. Zell, M. Diehn, 2020, Nature Reviews Clinical Oncology.

The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

Z. Szallasi, P. Kantoff, I. Csabai, 2017, Cancer.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

J. Meyerhardt, R. Schilsky, M. Bertagnolli, 2017, JAMA.

Benefits of Colonoscopic Surveillance and Prophylactic Colectomy in Patients with Hereditary Nonpolyposis Colorectal Cancer Mutations

Deborah Schrag, J. Garber, K. Kuntz, 1998, Annals of Internal Medicine.

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.

Deborah Schrag, Craig C Earle, C. Earle, 2006, Journal of the National Cancer Institute.

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.

J. Meyerhardt, A. Benson, C. Willett, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

J. Meyerhardt, R. Jain, A. Zhu, 2012, PloS one.

Delivering high-quality and affordable care throughout the cancer care continuum.

A. Abernethy, J. Goodwin, D. Aberle, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice

E. Fung, Minetta C. Liu, E. Klein, 2021, Cancers.

Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.

C. Earle, E. Trimble, J. Warren, 2006, Journal of the National Cancer Institute.

CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.

K. Kuntz, D. Schrag, F. Alarid-Escudero, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer

M. Gonen, M. Weiser, D. Schrag, 2010, Cancer.

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer

D. Schrag, K. Kehl, S. Greenwald, 2021, JAMA network open.

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer

I. Kohane, D. Schrag, N. Palmer, 2019, Cancer Immunology, Immunotherapy.

Pathologic stage is most prognostic of disease‐free survival in locally advanced rectal cancer patients after preoperative chemoradiation

M. Gonen, K. Goodman, M. Weiser, 2008, Cancer.

Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.

J. Meyerhardt, C. Fuchs, D. Schrag, 2014, Journal of the National Cancer Institute.

Who G ets A djuvant T reatment f or S tage I I a nd I II R ectal Cancer? I nsight F rom S urveillance, E pidemiology, a nd E nd Results-Medicare

C. Begg, J. Guillem, D. Schrag, 2001 .

Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma

Corwin M Zigler, Corwin M. Zigler, F. Dominici, 2016, Journal of Neuro-Oncology.

Hospitalization burden and survival among older glioblastoma patients.

F. Dominici, Yun Wang, D. Schrag, 2014, Neuro-oncology.

Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer

G. Schwartz, L. Saltz, D. Schrag, 2009, Investigational New Drugs.

The price tag on progress--chemotherapy for colorectal cancer.

Deborah Schrag, D. Schrag, 2004, The New England journal of medicine.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

L. Schwartz, M. Shah, N. Kemeny, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secular trends in colon and rectal cancer relative survival.

Eric J Feuer, Deborah Schrag, Karen M Kuntz, 2013, Journal of the National Cancer Institute.

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Arlene E. Chung, Amy P. Abernethy, Kimberly Shoenbill, 2019, J. Am. Medical Informatics Assoc..

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

R. Schilsky, R. Goldberg, H. Hurwitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regional variation in spending and survival for older adults with advanced cancer.

Dhruv B. Sharma, D. Schrag, J. Weeks, 2013, Journal of the National Cancer Institute.

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.

M. Somerfield, J. Ajani, H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.

I. Tannock, D. Schrag, R. Sullivan, 2017, The Lancet. Oncology.

Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis

D. Schrag, C. Hur, S. Goldie, 2015, Gut.

Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population.

C. Begg, D. Schrag, P. Bach, 2005, Urology.

The surgical learning curve for prostate cancer control after radical prostatectomy.

M. Kattan, P. Scardino, J. Eastham, 2007, Journal of the National Cancer Institute.

The influence of hospital volume on survival after resection for lung cancer.

C. Begg, D. Schrag, P. Bach, 2001, The New England journal of medicine.

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

J. Garber, K. Kuntz, D. Schrag, 2000, JAMA.

Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.

D. Schrag, M. Hanger, Morgan Hanger, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care

M. Khoury, R. Hiatt, K. Schulman, 2009, Public Health Genomics.

Comparative effectiveness of three platinum‐doublet chemotherapy regimens in elderly patients with advanced non–small cell lung cancer

D. Schrag, Aileen B Chen, J. Weeks, 2013, Cancer.

Challenges and opportunities for use of cost-effectiveness analysis.

D. Schrag, K. Yabroff, 2009, Journal of the National Cancer Institute.

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

K M Kuntz, J. Garber, K. Kuntz, 1997, The New England journal of medicine.

Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer

Rachel B. Keller, E. Cerami, J. Meyerhardt, 2023, JCO precision oncology.

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.

Ewout W Steyerberg, Hajime Uno, Deborah Schrag, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer

J. Warner, Gregory Riely, D. Schrag, 2021, JAMA network open.

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

J. Meyerhardt, C. Fuchs, A. Bullock, 2020, Cancers.

Author’s Response to “A Letter in Support of Real-World RECIST”

S. Khozin, D. Schrag, S. Griffith, 2020, Advances in Therapy.

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

Sandra D Griffith, Rebecca A Miksad, Geoff Calkins, 2019, JCO clinical cancer informatics.

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

S. Khozin, D. Schrag, S. Griffith, 2019, bioRxiv.

The APC I1307K allele and breast cancer risk

M. King, J. Satagopan, W. Foulkes, 1998, Nature Genetics.

The effect of disclosing life expectancy information on patients' prognostic understanding: secondary outcomes from a multicenter randomized trial of a palliative chemotherapy educational intervention.

H. Uno, K. Van Loon, A. Bullock, 2020, Journal of pain and symptom management.

Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes.

E. V. Van Allen, D. Schrag, K. Kehl, 2020, JCO clinical cancer informatics.

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

C. Ulrich, J. Cerhan, T. Sellers, 2013, Journal of the National Cancer Institute.

A Population-Based Analysis of Temporal Trends in the Incidence of Squamous Anal Canal Cancer in Relation to the HIV Epidemic

E. Stier, D. Schrag, S. Krown, 2005, Journal of acquired immune deficiency syndromes.

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Dhruv B. Sharma, D. Schrag, Aileen B Chen, 2012, JAMA.

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

M. Somerfield, H. Burstein, H. Garewal, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study.

J. Hayman, D. Schrag, Aileen B Chen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.

E. Elkin, D. Schrag, N. Mitra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions.

Deborah Schrag, E. Elkin, D. Schrag, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology guidance statement: the cost of cancer care.

Thomas J. Smith, P. Ubel, D. Schrag, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Precision Oncology: Who, How, What, When, and When Not?

Deborah Schrag, Edward S. Kim, Edward S Kim, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.

H. Uno, E. Basch, J. Villano, 2021 .

Germline variants associated with immunotherapy-related adverse events

A. Villani, M. Freedman, S. Shukla, 2022, medRxiv.

E. Basch, D. Schrag, J. Weeks, 2012, Journal of pain and symptom management.

Assessment of Between-Hospital Variation in Readmission and Mortality After Cancer Surgical Procedures

F. Dominici, S. Haneuse, S. Normand, 2018, JAMA network open.

Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

J. Meyerhardt, A. Benson, N. Petrelli, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome

K. Goodman, J. Guillem, L. Temple, 2008, Diseases of the colon and rectum.

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events.

M. Kris, E. Basch, H. Scher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer.

K. Kahn, N. Keating, R. Fletcher, 2014, Journal of the National Cancer Institute.

Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.

M. Gönen, M. Weiser, D. Schrag, 2009, Journal of Clinical Oncology.

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Jeffrey W. Clark, W. Goessling, R. Heist, 2020, Investigational New Drugs.

Evaluation of different recall periods for the US National Cancer Institute’s PRO-CTCAE

E. Basch, A. Bennett, J. Sloan, 2017, Clinical trials.

Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.

David Artz, Alexia Iasonos, Deborah Schrag, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can Differences in Bowel Function After Surgery for Rectal Cancer Be Identified by the European Organization for Research and Treatment of Cancer Quality of Life Instrument?

J. Guillem, L. Temple, M. Weiser, 2007, Annals of Surgical Oncology.

Impact of oncology‐related direct‐to‐consumer advertising

D. Schrag, J. Weeks, M. Hassett, 2013, Cancer.

Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer.

H. Prigerson, D. Schrag, A. Enzinger, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer.

J. Hayman, D. Schrag, Aileen B Chen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Patient and Family Outpatient Complaints as a Strategy to Prioritize Efforts to Improve Cancer Care Delivery.

D. Schrag, A. Cronin, J. Mack, 2017, Joint Commission journal on quality and patient safety.

Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium.

Ronald C. Chen, C. Greenberg, D. Schrag, 2013, Journal of comparative effectiveness research.

Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients: What Is the Impact of Data Source?

W. Lawrence, A. Mariotto, J. Warren, 2009, Medical Care.

Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients

Angela Mariotto, Deborah Schrag, A. Mariotto, 2009, Medical care.

Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.

S. Haneuse, D. Sargent, D. Schrag, 2016, Journal of the National Cancer Institute.

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market

D. Schrag, Y. Shih, Ying Xu, 2021, JNCI cancer spectrum.

Lifestyle prescriptions for cancer survivors and their communities

D. Mozaffarian, D. Schrag, M. Lajous, 2011, Journal of internal medicine.

The Survivorship Care Plan: What, Why, How, and for Whom

C. Earle, S. Woolf, P. Ganz, 2007 .

Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts

Nikki M. Carroll, Nathan Taback, Debra P Ritzwoller, 2014, Medical care.

Linking Tumor Registry and Medicaid Claims to Evaluate Cancer Care Delivery

J. Warren, D. Schrag, B. Virnig, 2009, Health care financing review.

Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.

A. Benson, M. Weiser, J. Skibber, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community

Wei Jiang, S. Schnitt, L. Habel, 2016, Breast Cancer Research and Treatment.

Using propensity scores to estimate the cost–effectiveness of medical therapies

Nandita Mitra, Alka Indurkhya, Deborah Schrag, 2006, Statistics in medicine.

Fragmentation of Care for Frequently Hospitalized Urban Residents

E. Elkin, D. Schrag, P. Bach, 2006, Medical care.

Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.

C. Huttenhower, J. Meyerhardt, S. Ogino, 2012, Archives of surgery.

Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy

M. Gonen, J. Guillem, L. Temple, 2008, Diseases of the colon and rectum.

Do older Americans undergo stoma reversal following low anterior resection for rectal cancer?

S. Lipsitz, C. Greenberg, D. Schrag, 2013, The Journal of surgical research.

Young Age Influences Treatment but not Outcome of Colon Cancer

J. Guillem, P. Paty, L. Temple, 2007, Annals of Surgical Oncology.

Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer.

H. Uno, D. Schrag, B. Landon, 2014, Health affairs.

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Jay K. Harness, Sandra A. Mitchell, Amylou C. Dueck, 2016, Health and Quality of Life Outcomes.

Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.

Arlene E. Chung, E. Basch, A. Bennett, 2020, JCO clinical cancer informatics.

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

T. Kolevska, L. Minasian, E. Basch, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

A. Abernethy, L. Minasian, E. Basch, 2011, Translational behavioral medicine.

Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.

J. Meyerhardt, D. Schrag, H. Sanoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.

Neetu Chawla, Angela Mariotto, Deborah Schrag, 2014, Annals of epidemiology.

Resurrecting treatment histories of dead patients: a study design that should be laid to rest.

C. Begg, D. Schrag, P. Bach, 2004, JAMA.

Oncology Patient Portal Enrollment at a Comprehensive Cancer Center: A Quality Improvement Initiative.

D. Schrag, C. Barysauskas, J. Jacobson, 2018, Journal of oncology practice.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

M. Socinski, L. Minasian, D. Lake, 2017, JAMA oncology.

Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

J. Gagne, L. Minasian, E. Basch, 2014, Quality of Life Research.

The impact of smoking on radical cystectomy complications increases in elderly patients

Steven L. Chang, A. Kibel, J. Gore, 2020, Cancer.

Properties of analysis methods that account for clustering in volume–outcome studies when the primary predictor is cluster size

Katherine S Panageas, Colin B Begg, Deborah Schrag, 2007, Statistics in medicine.

Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

M. Gonen, K. Goodman, J. Guillem, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of potentially avoidable hospitalizations in patients with GI cancer.

H. Uno, J. Meyerhardt, C. Fuchs, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)

E. Basch, M. Weiser, L. Saltz, 2019, Clinical trials.

Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions.

J. Niland, K. Goodman, M. Weiser, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

CLEP_A_373291 1135..1144

S. Schneeweiss, D. Schrag, Kueiyu Joshua Lin, 2022 .

Reply to H. Hartmann et al

J. Meyerhardt, D. Schrag, Ling Li, 2012 .

Reply to M. Koshy

D. Schrag, Aileen B Chen, 2011 .

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

Robert H Fletcher, Katherine L Kahn, Deborah Schrag, 2010, JAMA.

Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer.

K. Rosenzweig, D. Schrag, P. Bach, 2006, International journal of radiation oncology, biology, physics.

Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?

D. Schrag, K. Ng, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of Information Technology: Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities

Kai Lin, Ethan Basch, David Artz, 2007, J. Am. Medical Informatics Assoc..

Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer

D. Schrag, Aileen B Chen, A. Cronin, 2018, Advances in radiation oncology.

Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer.

D. Schrag, M. Hornbrook, J. Weeks, 2012, The Oncologist.

The Impact of a Prior Diagnosis of Barrett’s Esophagus on Esophageal Adenocarcinoma Survival

D. Schrag, C. Kong, C. Hur, 2017, The American Journal of Gastroenterology.

Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis.

J. Niland, A. Benson, M. Weiser, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures.

Katherine L Kahn, Deborah Schrag, Andrew K Stewart, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer

P. Pandharipande, D. Schrag, C. Kong, 2018, Cancer medicine.

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

N. Schultz, J. Warner, R. Shen, 2021, JAMA oncology.

Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

M. Schymura, R. Goldberg, D. Schrag, 2012, Cancer.

Physician visits prior to treatment for clinically localized prostate cancer.

C. Begg, E. Elkin, T. Jang, 2010, Archives of internal medicine.

A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

R. Schilsky, H. McLeod, R. Goldberg, 2007 .

Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data.

H. Uno, A. Tosteson, D. Schrag, 2019, JCO clinical cancer informatics.

Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

L. Minasian, J. Sloan, B. Reeve, 2012 .

Hospital variation in sphincter preservation for elderly rectal cancer patients.

S. Lipsitz, M. Zinner, C. Greenberg, 2014, The Journal of surgical research.

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

H. Uno, Lee-Jen Wei, D. Schrag, 2018, JAMA oncology.

Primary care physicians who treat blacks and whites.

Deborah Schrag, Hoangmai H Pham, J Lee Hargraves, 2004, The New England journal of medicine.

Comparing Intensity of Follow-up Tests After Surgery for Colorectal Cancer

K. Van Loon, D. Schrag, R. Volk, 2020 .

Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer

K. Van Loon, C. Greenberg, D. Winchester, 2018, JAMA.

Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality: The Role of Physician-level Variations in Care

D. Schrag, A. Ang, M. Wong, 2016, Medical care.

Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era

D. Schrag, K. Kehl, M. Hassett, 2020, Cancer medicine.

Meeting the 12 lymph node (LN) benchmark in colon cancer

J. Niland, A. Benson, M. Weiser, 2010, Journal of surgical oncology.

Changes in access to screening mammography, 2008–2011

E. Elkin, D. Schrag, C. L. Atoria, 2013, Cancer Causes & Control.

Overuse of Diagnostic Brain Imaging Among Patients With Stage IA Non-Small Cell Lung Cancer.

D. Schrag, Aileen B Chen, Y. Colson, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry.

Benjamin E. Gross, Stuart M. Gardos, N. Schultz, 2020, Cancer discovery.

When you look matters: the effect of assessment schedule on progression-free survival.

Katherine S Panageas, Deborah Schrag, L. Ben-Porat, 2007, Journal of the National Cancer Institute.

A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

W. Goessling, R. Heist, P. Enzinger, 2013 .

National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010

F. Dominici, Yun Wang, D. Schrag, 2014, Cancer.

Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.

J. Meyerhardt, C. Fuchs, P. Enzinger, 2013, The oncologist.

Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis.

C. Begg, E. Elkin, M. Gonen, 2008, Journal of the National Cancer Institute.

Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer: A Randomized Clinical Trial.

H. Uno, K. Van Loon, A. Bullock, 2020, JAMA oncology.

Barriers to Electronic Patient-Reported Outcome Measurement Among Patients with Cancer and Limited English Proficiency

D. Schrag, M. Hassett, Anna Revette, 2022, JAMA network open.

Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01).

S. Edge, C. Greenberg, D. Winchester, 2022, Journal of the National Cancer Institute.

Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.

C. Greenberg, D. Schrag, N. Stout, 2012, Journal of the National Cancer Institute.

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.

Wei Jiang, J. Niland, S. Edge, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

High Intensity of End-of-Life Care Among Adolescent and Young Adult Cancer Patients in the New York State Medicaid Program

F. Boscoe, M. Schymura, F. Gesten, 2015, Medical care.

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes

L. Tian, H. Uno, Lee-Jen Wei, 2019, JNCI cancer spectrum.

Insurance Networks and Access to Affordable Cancer Care.

N. Keating, D. Schrag, S. Giordano, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer

M. Weiser, L. Schwartz, O. Akin, 2012, European Radiology.

Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.

J. Meyerhardt, C. Fuchs, D. Schrag, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.

M. Kattan, P. Scardino, J. Eastham, 2008, European urology.

Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.

D. Schrag, B. Wolpin, Jiping Wang, 2021, JAMA oncology.

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer

H. Uno, A. Tosteson, D. Schrag, 2018, JAMA network open.

Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation

H. Uno, C. Greenberg, D. Schrag, 2017, JAMA oncology.

Translation of Patient-Reported Outcomes in Oncology Clinical Trials to Everyday Practice

D. Schrag, S. Wong, G. Brooks, 2019, Annals of Surgical Oncology.

Adding Patient-Reported Outcomes to Medicare's Oncology Value-Based Payment Model.

E. Basch, D. Schrag, L. Wilfong, 2020, JAMA.

Use of surgery among elderly patients with stage IV colorectal cancer.

L. Temple, L. Saltz, D. Schrag, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study.

Hajime Uno, Deborah Schrag, Nathan Taback, 2014, Annals of internal medicine.

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

C. Earle, A. Grothey, A. Venook, 2015 .

Attribution of deaths following cancer treatment.

Colin B Begg, Deborah Schrag, C. Begg, 2002, Journal of the National Cancer Institute.

Enhancing cancer registry data to promote rational health system design.

Deborah Schrag, D. Schrag, 2008, Journal of the National Cancer Institute.

Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment

F. Boscoe, M. Schymura, F. Gesten, 2016, Cancer.

Measuring colorectal cancer care quality for the publicly insured in New York State

F. Boscoe, M. Schymura, D. Schrag, 2012, Cancer medicine.

Use of high technology imaging for surveillance of early stage breast cancer

C. Sima, L. Liberman, D. Schrag, 2011, Breast Cancer Research and Treatment.

How often is adjuvant FOLFOX (Adj FOLFOX) discontinued for toxicity among colon cancer patients in the routine care setting?

J. Niland, A. Benson, M. Weiser, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics

Hoangmai H Pham, Hoangmai H. Pham, D. Schrag, 2007, Medical care.

Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment.

Deborah Schrag, Francis P Boscoe, G. Abel, 2011, The oncologist.

Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER–Medicare study

D. Schrag, C. Hur, Jennifer M. Yeh, 2017, Gastric Cancer.

Cost‐effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first‐line therapy for metastatic colorectal carcinoma

D. Sargent, B. Hillner, C. Fuchs, 2005, Cancer.

Meeting the 12 lymph nodes (LN) benchmark in colorectal cancer surgery: A comparison of NCCN and SEER data

C. Earle, M. Weiser, P. Engstrom, 2007 .

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

W. Goessling, J. Meyerhardt, C. Fuchs, 2013, The oncologist.

Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).

C. Azzoli, J. Meyerhardt, C. Fuchs, 2016 .

Changes in the availability of screening mammography, 2000–2010

E. Elkin, D. Schrag, P. Bach, 2013, Cancer.

Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ

S. Edge, C. Greenberg, L. Habel, 2014, Annals of Surgical Oncology.

Medicare Spending, Utilization, and Quality in the Oncology Care Model.

R. Osarogiagbon, D. Schrag, S. Mullangi, 2021, Journal of the American Medical Association (JAMA).

Racial variation in willingness to trade financial resources for life‐prolonging cancer treatment

M. Fouad, D. Schrag, C. Kiefe, 2011, Cancer.

Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.

Q. Trinh, D. Schrag, 2014, JAMA internal medicine.

Evaluation of the Duplication of Staging CT Scans for Localized Colon Cancer in a Medicare Population

M. Hernán, D. Schrag, X. García-Albéniz, 2014, Medical care.

What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups

M. Fouad, D. Schrag, M. Pisu, 2013, Supportive Care in Cancer.

Cholera Incidence and El Niño–Related Higher Ambient Temperature

D. Schrag, 2000 .

Quality of life (QOL) and toxicity among patients in CALGB 80405.

H. Lenz, A. Venook, D. Schrag, 2013 .

Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond.

Michael Hogarth, Joseph Lipscomb, Deborah Schrag, 2015, Journal of the National Cancer Institute.

Title Early dissemination of bevacizumab for advanced colorectal cancer : a prospective cohort study Permalink

K. Kahn, S. Grambow, P. Catalano, 2011 .

Well‐being beyond the bladder. How do we improve the overall health of patients with bladder cancer?

D. Schrag, Justin C. Brown, M. Mossanen, 2018, BJU international.

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer

D. Schrag, Aileen B Chen, A. Cronin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinician perspectives on potentially avoidable hospitalizations in patients with cancer.

D. Schrag, G. Brooks, J. Jacobson, 2015, JAMA oncology.

Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer

H. Uno, D. Schrag, K. Kehl, 2020, JAMA network open.

Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test.

E. Fung, Minetta C. Liu, E. Klein, 2021 .

Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision.

D. Schrag, 2016, JAMA.

Patient Demographic and Tumor Characteristics Influencing Oncologist Follow-Up Frequency in Older Breast Cancer Survivors

Maureen A. Smith, C. Greenberg, D. Schrag, 2013, Annals of Surgical Oncology.

Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

K. Kahn, N. Keating, K. Goodman, 2014, Journal of oncology practice.

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.

M. Somerfield, J. Ajani, H. Burstein, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

Seung-Yong Jeong, J. Guillem, D. Schrag, 2005, Journal of the National Cancer Institute.

A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach

J. Warner, Gregory Riely, B. Park, 2022, JCO clinical cancer informatics.

Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors

R. Maki, L. Saltz, G. Ku, 2009, Cancer investigation.

Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.

Neha M Jain, N. Schultz, J. Warner, 2021 .

903O A prospective study of a multi-cancer early detection blood test

E. Klein, L. Nadauld, D. Schrag, 2022, Annals of Oncology.

Population-Based Assessment of Determining Treatments for Prostate Cancer

R. MacDonald, I. Rutks, T. Guzzo, 2016 .

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

K. Kahn, R. Fletcher, P. Ganz, 2010, JAMA.

ArticlesEffect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients

C. Earle, E. Trimble, D. Bodurka, 2006 .

Patient-oncologist cost communication, financial distress, and medication adherence.

A. Abernethy, J. Tulsky, P. Ubel, 2014, Journal of oncology practice.

Rapidity and modality of imaging for acute low back pain in elderly patients.

Hoangmai H Pham, D. Schrag, Beny Wu, 2009, Archives of internal medicine.

Talking with patients about dying.

D. Schrag, J. Weeks, J. Mack, 2013, The New England journal of medicine.

PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)

N. Kemeny, J. Herndon, D. Schrag, 2005 .

A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303

R. Goldberg, M. Mulcahy, D. Schrag, 2007 .

Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors

R. Maki, L. Saltz, G. Ku, 2009, Cancer Investigation.

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.

J. Niland, A. Benson, M. Weiser, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.

W. Goessling, J. Meyerhardt, C. Fuchs, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic stage is most prognostic of disease‐free survival in locally advanced rectal cancer patients after preoperative chemoradiation

M. Gonen, K. Goodman, M. Weiser, 2008, Cancer.

Adjuvant and Neoadjuvant Therapy for Colorectal Carcinoma

D. Schrag, W. Wong, Anne Y. Lin, 2009 .

Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer.

D. Schrag, M. Hornbrook, J. Weeks, 2012, The oncologist.

Patient-oncologist cost communication, financial distress, and medication adherence.

J. Tulsky, P. Ubel, D. Schrag, 2014, Journal of oncology practice.

Application of Information Technology: Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities

E. Basch, H. Scher, A. Iasonos, 2007, J. Am. Medical Informatics Assoc..

Survival Disparities by Race and Ethnicity in Early Esophageal Cancer

D. Schrag, C. Kong, C. Hur, 2018, Digestive Diseases and Sciences.

Intensity of Medical Interventions between Diagnosis and Death in Patients with Advanced Lung and Colorectal Cancer: A CanCORS Analysis.

H. Uno, N. Keating, D. Schrag, 2016, Journal of palliative medicine.

Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer.

D. Schrag, J. Ayanian, A. Cronin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients: What Is the Impact of Data Source?

W. Lawrence, A. Mariotto, D. Schrag, 2009, Medical care.

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

C. Ulrich, J. Cerhan, T. Sellers, 2013, Journal of the National Cancer Institute.

L. Minasian, E. Basch, A. Bennett, 2017, International journal of radiation oncology, biology, physics.

Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California.

F. Boscoe, M. Schymura, F. Gesten, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer.

P. Maciejewski, H. Prigerson, S. Block, 2009, JAMA.

Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision.

D. Schrag, 2016, JAMA.

Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial.

E. Basch, A. Bennett, B. Reeve, 2021, Journal of Clinical Oncology.

Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review

D. Schrag, Varshini S Odayar, Christopher R. Manz, 2021, Cancer medicine.

Composite grading algorithm for National Cancer Institute’s PRO-CTCAE.

M. Bertagnolli, E. Basch, A. Bennett, 2020 .

Evaluating the use of web versus mobile devices for ePRO reporting and severe symptom responses at 6 cancer centers.

R. Osarogiagbon, D. Schrag, M. Hassett, 2022, Journal of Clinical Oncology.

A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care

R. Hiatt, K. Schulman, M. Donaldson, 2009, Public Health Genomics.

Patient-reported health literacy and numeracy among new patients seeking consultation at a comprehensive cancer center.

D. Schrag, E. Lepisto, M. Hassett, 2020 .

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer

D. Schrag, Aileen B Chen, A. Cronin, 2014, Journal of Thoracic Oncology.